The Five Medtech Trends Reshaping the Industry in 2026
An analysis of five key medtech trends for 2026, covering China's VBP expansion, outpatient care shifts, supply chain pressures, GLP-1 therapy impacts, and platform-based competition.
Executive Summary
The medtech landscape in 2026 is defined by five interconnected trends: the expansion of China's volume-based procurement (VBP), the accelerating shift of procedures to ambulatory surgical centers (ASCs), persistent global trade and supply chain pressures, the behavioral and clinical impact of GLP-1 receptor agonists, and the emergence of enabling technologies as the foundation of platform-based competition. These forces are reshaping market access, manufacturing strategy, care delivery, and competitive differentiation. Companies that adapt their portfolio strategies, commercial models, and supply chain resilience will be best positioned for sustained growth.
Introduction
The medical technology sector is entering a period of accelerated change, where structural forces—rather than incremental innovation alone—are determining market winners. From pricing reforms in Mainland China to the metabolic effects of GLP-1 drugs, the industry must navigate a complex interplay of regulatory, economic, and clinical shifts. Drawing on proprietary data and expert analysis, this article explores five pivotal trends that will define medtech strategy in 2026 and beyond.
Scientific and Industry Background
Medtech encompasses a broad range of products—from implantable devices and surgical instruments to diagnostic equipment and digital health platforms. Historically, growth was driven by new product introductions and procedure volume expansion. However, recent years have seen a convergence of policy changes, macroeconomic pressures, and technological advances that are rewriting the rules of competition.
1. Mainland China’s VBP Expansion
China's volume-based procurement program, initially designed to reduce costs and expand access, has evolved into a sophisticated market-structuring mechanism. The latest national VBP round introduces anchor-price logic, deeper price compression, and allocation rules that favor domestic manufacturers. Multinational corporations face pressure to lower prices while maintaining quality, and the pricing dynamics are influencing negotiations in other markets.
Evidence: Clarivate data show that VBP has led to average price reductions of 50–90% for certain device categories, with domestic companies gaining market share. The impact is most pronounced in coronary stents, orthopedic implants, and dialysis products.
Industry Impact: Companies must reassess portfolio strategies, localize manufacturing, and develop value-based offerings. VBP is accelerating domestic innovation as Chinese firms invest in R&D to compete globally.
2. Outpatient and ASC Settings
The migration of procedures from hospitals to outpatient settings continues, reinforced by CMS's 2026 OPPS/ASC Final Rule, which expands the ASC Covered Procedure List and phases out the inpatient-only list. Higher-acuity procedures such as cardiac ablation are now eligible for ASC reimbursement when clinically appropriate.
Evidence: The proportion of total knee arthroplasties performed in ASCs rose from 5% in 2019 to over 25% in 2025, according to CMS claims data. Similar trends are seen in spine and cardiology procedures.
Industry Impact: Medtech companies must adapt product designs for ASC workflows, develop economic value propositions that demonstrate cost savings, and restructure sales forces to reach this growing customer segment.
3. Global Trade and Supply Chain Pressures
Tariffs, geopolitical tensions, and fluctuating material costs are challenging just-in-time manufacturing models. Companies are diversifying sourcing, reshoring critical production, and investing in supply chain digitization.
Evidence: A 2025 survey by the Advanced Medical Technology Association (AdvaMed) found that 70% of medtech firms experienced supply chain disruptions in the past year, with semiconductor and specialty metals shortages most cited.
Industry Impact: Larger manufacturers with vertically integrated supply chains gain competitive advantage. Smaller firms may need to consolidate or partner to achieve resilience. Manufacturing geography is becoming a strategic asset.
4. GLP-1 Therapies Reshaping Care Pathways
Glucagon-like peptide-1 receptor agonists have rapidly expanded beyond diabetes into weight management, reducing demand for some bariatric procedures while creating new opportunities in cardiovascular monitoring and sleep apnea devices.
Evidence: Bariatric surgery volumes in the U.S. declined 15% in 2025 compared to 2023, coinciding with GLP-1 prescriptions rising to over 30 million patients. However, procedures like gastric bypass remain stable due to greater weight loss and durability.
Industry Impact: Companies in metabolic surgery, continuous glucose monitoring, and cardiac implantables must model the GLP-1 effect on procedure volumes and develop combination therapy strategies.
5. Enabling Technologies and Platform Competition
Robotics, advanced imaging, navigation, and digital workflow software are no longer standalone tools but integrated platforms that anchor service lines and create data-driven value.
Evidence: The surgical robotics market is projected to exceed $20 billion by 2030, with open-platform systems gaining traction alongside incumbent integrated systems. Companies are investing in AI-powered planning and intraoperative intelligence.
Industry Impact: Platform-based competition drives customer lock-in, enables recurring revenue through software and service contracts, and differentiates through clinical outcomes and efficiency gains.
Clinical and Regulatory Perspective
Each trend carries regulatory implications. China's NMPA has aligned some standards with international norms, but VBP creates distinct regulatory pathways for domestic versus imported devices. The ASC shift requires CMS to continuously update reimbursement codes and quality measures. Supply chain resilience is being addressed by FDA guidance on risk management and by international harmonization efforts. GLP-1 effects on surgical outcomes require new clinical studies. Platform technologies raise cybersecurity and interoperability concerns that regulators are still addressing.
Future Outlook
Over the next 5–15 years, these trends will intensify. China's domestic medtech industry will become a major global competitor. ASCs will handle more complex procedures, demanding miniaturized and cost-effective devices. Supply chains will become more regionalized. GLP-1 therapies may evolve into chronic disease management platforms, reducing surgical volumes for some conditions while increasing monitoring needs. Platform ecosystems will consolidate, with AI and data analytics becoming core to competitive strategy.
Conclusion
Medtech in 2026 is not simply about better devices; it is about adapting to structural shifts in pricing, care settings, geopolitics, therapeutic paradigms, and technology integration. Companies that proactively respond to these trends—through portfolio rationalization, manufacturing flexibility, and platform investments—will lead the next wave of industry growth.
Key Takeaways
- China's VBP is reshaping global medtech pricing and accelerating domestic innovation.
- ASC expansion requires adapted products and commercial models.
- Supply chain resilience is a strategic imperative, not just an operational concern.
- GLP-1 therapies are altering procedure volumes and creating new device opportunities.
- Platform-based competition is redefining differentiation and customer relationships.